Remko van Leeuwen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5714747/publications.pdf

Version: 2024-02-01

20 papers

1,389 citations

623734 14 h-index 752698 20 g-index

20 all docs

20 docs citations

times ranked

20

1299 citing authors

#	Article	IF	Citations
1	Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. Lancet Infectious Diseases, The, 2021, 21, 275-285.	9.1	27
2	Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. PLoS Neglected Tropical Diseases, 2021, 15, e0009732.	3.0	6
3	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEATOO1/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 628-639.	3.0	7
4	Eradication of meticillin-resistant Staphylococcus aureus from human skin by the novel LL-37-derived peptide P10 in four pharmaceutical ointments. International Journal of Antimicrobial Agents, 2019, 54, 610-618.	2,5	9
5	Where is the â€~global' in the European Union's Health Research and Innovation Agenda?. BMJ Global Health, 2019, 4, e001559.	4.7	2
6	Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet, The, 2014, 384, 1942-1951.	13.7	158
7	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. Aids, 2003, 17, 987-999.	2.2	151
8	Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. Aids, 2001, 15, 2423-2429.	2.2	34
9	A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). Aids, 2000, 14, 1349-1356.	2.2	24
10	Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. Aids, 2000, 14, 1155-1161.	2.2	50
11	A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. Aids, 2000, 14, 1375-1382.	2.2	28
12	Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. Aids, 2000, 14, 2895-2902.	2.2	342
13	Reliability of tuberculin purified derivative skin testing and delayed-type hypersensitivity skin test anergy in HIV-infected homosexual men, at risk of tuberculosis. Aids, 1999, 13, 1784.	2.2	5
14	Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet, The, 1998, 352, 185-190.	13.7	148
15	Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo. Aids, 1998, 12, 1169-1176.	2.2	7
16	Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. Aids, 1998, 12, 2275-2280.	2.2	61
17	Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. Aids, 1998, 12, 35-41.	2.2	165
18	Lamivudineâ€Resistant Human Immunodeficiency Virus Type 1 Variants (184V) Require Multiple Amino Acid Changes to Become Coâ€Resistant to Zidovudine In Vivo. Journal of Infectious Diseases, 1997, 176, 398-405.	4.0	99

#	Article	IF	CITATIONS
19	Treatment of HIV Infection. Drug Safety, 1996, 15, 176-187.	3.2	25
20	Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study. British Journal of Haematology, 1991, 78, 319-324.	2.5	41